Edges in Network
| Network | GSE16446_egf1520 - GSE16446 - SiGN-BN HC+Bootstrap |
| Network Description | Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial |
| Node | GAPDH |
| Upstream (Parents) |
|---|
| (<<) ACTB → GAPDH |
| (<<) CFL1 → GAPDH |
| (<<) CYB5R3 → GAPDH |
| (<<) DAZAP2 → GAPDH |
| (<<) ENO1 → GAPDH |
| (<<) HSP90AB1 → GAPDH |
| (<<) HSPA8 → GAPDH |
| (<<) MCL1 → GAPDH |
| (<<) RHOA → GAPDH |
| (<<) RPS16 → GAPDH |
| Downstream (Children) |
|---|
| GAPDH → ACTN1 (>>) |
| GAPDH → ADAM17 (>>) |
| GAPDH → ANXA2 (>>) |
| GAPDH → ATF4 (>>) |
| GAPDH → ATN1 (>>) |
| GAPDH → ATP2A2 (>>) |
| GAPDH → CCDC3 (>>) |
| GAPDH → CREB1 (>>) |
| GAPDH → CRK (>>) |
| GAPDH → CSTB (>>) |
| GAPDH → DNM1L (>>) |
| GAPDH → EIF6 (>>) |
| GAPDH → EMG1 (>>) |
| GAPDH → EMILIN2 (>>) |
| GAPDH → ENO2 (>>) |
| GAPDH → FERMT1 (>>) |
| GAPDH → FHIT (>>) |
| GAPDH → GLRX (>>) |
| GAPDH → GPX4 (>>) |
| GAPDH → HES1 (>>) |
| GAPDH → HK2 (>>) |
| GAPDH → HMGCS1 (>>) |
| GAPDH → IFITM3 (>>) |
| GAPDH → ITPR3 (>>) |
| GAPDH → JUN (>>) |
| GAPDH → KLF6 (>>) |
| GAPDH → LRP6 (>>) |
| GAPDH → MOBKL2C (>>) |
| GAPDH → MT1F (>>) |
| GAPDH → MT1G (>>) |
| GAPDH → MT1P2 (>>) |
| GAPDH → MTAP (>>) |
| GAPDH → NBL1 (>>) |
| GAPDH → NFATC3 (>>) |
| GAPDH → NUPR1 (>>) |
| GAPDH → PFDN1 (>>) |
| GAPDH → PKM2 (>>) |
| GAPDH → PPIF (>>) |
| GAPDH → PRKCH (>>) |
| GAPDH → RNF5 (>>) |
| GAPDH → ROCK2 (>>) |
| GAPDH → RPIA (>>) |
| GAPDH → RPL35 (>>) |
| GAPDH → RPL36 (>>) |
| GAPDH → SEH1L (>>) |
| GAPDH → SFXN4 (>>) |
| GAPDH → SHC2 (>>) |
| GAPDH → STAT3 (>>) |
| GAPDH → SULT4A1 (>>) |
| GAPDH → TAGLN2 (>>) |
| GAPDH → THOC4 (>>) |
| GAPDH → TK2 (>>) |
| GAPDH → TNFRSF1A (>>) |
| GAPDH → VEGFA (>>) |
